Lorlatinib and alectinib are two pivotal drugs used in the treatment of lung cancer, particularly those with an ALK rearrangement. These medications, often prescribed as targeted therapies, have garnered significant attention in the oncology community for their efficacy and minimal side effects. This article delves into the comparative analysis of lorlatinib versus alectinib, highlighting their...